A Phase 2 Partially Observer-Blind Randomized Controlled Multicenter Dose-Ranging and Formulation-Finding Study of a New Novartis Meningococcal B Recombinant Vaccine Evaluating the Safety and Immunogenicity When Given Concomitantly With Routine Vaccines in 2-month-old Infants

Trial Profile

A Phase 2 Partially Observer-Blind Randomized Controlled Multicenter Dose-Ranging and Formulation-Finding Study of a New Novartis Meningococcal B Recombinant Vaccine Evaluating the Safety and Immunogenicity When Given Concomitantly With Routine Vaccines in 2-month-old Infants

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2015

At a glance

  • Drugs Meningococcal vaccine group B OMV Novartis (Primary)
  • Indications Meningococcal group B infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 22 Feb 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
    • 22 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Oct 2011 Planned end date changed from 1 Sep 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top